Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L7a (RPL7A) is a key structural component of the large (60S) ribosomal subunit, belonging to the L7AE family of ribosomal proteins. It functions in the cytoplasm as part of the ribosome, catalyzing protein synthesis (translation). RPL7A contains two RNA-binding domains and participates directly in the assembly and functioning of ribonucleoprotein complexes. Beyond its structural roles, RPL7A can interact with a subset of nuclear hormone receptors, such as the thyroid hormone receptor, modulating their ability to activate gene transcription by blocking receptor-DNA binding. Expression of RPL7A can be altered in disease contexts—including upregulation and downregulation in breast cancer and osteosarcoma, respectively—suggesting roles in tumor progression and diagnosis. Gene rearrangement involving RPL7A and the trk proto-oncogene can result in oncogenic proteins. RPL7A is not a typical drug target, but it is of pathological and potential biomarker relevance in several diseases, notably certain cancers and genetic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L7a (RPL7A).